Payment overview · 2025
General Payments
$206,576.34
198 reported records · 10 companies
Healthcare provider profile · identity verified
Paul Brian Jacob, D.O.
Allopathic & Osteopathic Physicians|Orthopaedic Surgery|Adult Reconstructive Orthopaedic Surgery · OKLAHOMA CITY, OK · NPI 1548433345
Verified facts
What the public records show
CMS Open Payments records show Paul Brian Jacob, D.O. received $206,576.34 in general payments during 2025 across 198 reported records.
Stryker Corporation accounted for 99.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Zilretta.
Pacira Pharmaceuticals Incorporated reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zilretta as an associated drug or biological on 3269 records involving 2291 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Zilretta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $206,103.21 | 99.8% | 187 | 2025 |
| Think Surgical, Inc. | Unresolved — no canonical attribution shown | $157.50 | 0.1% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $135.48 | 0.1% | 2 | 2025 |
| Avanos Medical | Unresolved — no canonical attribution shown | $49.82 | 0.0% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $44.92 | 0.0% | 2 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $22.93 | 0.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.87 | 0.0% | 1 | 2025 |
| Heron Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.20 | 0.0% | 1 | 2025 |
| DeRoyal Industries, Inc. | Unresolved — no canonical attribution shown | $15.46 | 0.0% | 1 | 2025 |
| Molnlycke Health Care US, LLC | Unresolved — no canonical attribution shown | $10.95 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $178,887.50 | 52 |
| Travel and Lodging | $22,838.00 | 66 |
| Food and Beverage | $4,850.84 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MAKO Normalized: mako |
Device | Stryker Corporation | $165,368.59 | 171 | 2025 |
Source payment records
|
|||||
| ACCOLADE Normalized: accolade |
Device | Stryker Corporation | $34,088.89 | 8 | 2025 |
Source payment records
|
|||||
| TRIATHLON Normalized: triathlon |
Device | Stryker Corporation | $8,505.34 | 8 | 2025 |
Source payment records
|
|||||
| GMRS Normalized: gmrs |
Device | Stryker Corporation | $5,665.39 | 3 | 2025 |
Source payment records
|
|||||
| INSIGNIA Normalized: insignia |
Device | Stryker Corporation | $4,675.00 | 1 | 2025 |
Source payment records
|
|||||
| AEQUALIS Normalized: aequalis |
Device | Stryker Corporation | $3,850.00 | 1 | 2025 |
Source payment records
|
|||||
| TRITANIUM Normalized: tritanium |
Device | Stryker Corporation | $2,612.50 | 2 | 2025 |
Source payment records
|
|||||
| TMINI Miniature Robotic System Normalized: tmini miniature robotic system |
Medical Supply | Think Surgical, Inc. | $157.50 | 1 | 2025 |
Source payment records
|
|||||
| Persona Normalized: persona |
Device | Zimmer Biomet Holdings, Inc. | $120.66 | 1 | 2025 |
Source payment records
|
|||||
| PNB AND ACCESSORIES Normalized: pnb and accessories |
Device | Avanos Medical | $49.82 | 1 | 2025 |
Source payment records
|
|||||
| Zilretta Normalized: zilretta |
Drug | Pacira Pharmaceuticals Incorporated | $44.92 | 2 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| Iovera Normalized: iovera |
Device | Pacira Pharmaceuticals Incorporated | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| ZYNRELEF Normalized: zynrelef |
Drug | Heron Therapeutics, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Flex Negative Pressure Wound Therapy System Normalized: prospera flex negative pressure wound therapy system |
Device | DeRoyal Industries, Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| mymobility Platform Normalized: mymobility platform |
Device | Zimmer Biomet Holdings, Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| Avance Normalized: avance |
Device | Molnlycke Health Care US, LLC | $10.95 | 1 | 2025 |
Source payment records
|
|||||
| Mepilex Border Post-Op Normalized: mepilex border post op |
Device | Molnlycke Health Care US, LLC | $10.95 | 1 | 2025 |
Source payment records
|
|||||
| Mepilex Border Post-Op Ag Normalized: mepilex border post op ag |
Device | Molnlycke Health Care US, LLC | $10.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Zilretta zilretta |
2025 | Zilretta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals Incorporated Exact reporting entity; no affiliate inference |
2025 | Zilretta open payments reported associated product |
CMS Open Payments — General Payments 3269 supporting records · 2291 recipient NPIs · example record 1250264199 |
Zilretta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 544 | 267 |
| Amoxicillin | Amoxicillin | 534 | 258 |
| Famotidine | Famotidine | 474 | 447 |
| Doxycycline Hyclate | Doxycycline Hyclate | 433 | 399 |
| Tizanidine Hcl | Tizanidine Hcl | 321 | 231 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 294 | 164 |
| Ibuprofen | Ibuprofen | 283 | 205 |
| Dexamethasone | Dexamethasone | 255 | 242 |
| Naloxone Hcl | Naloxone Hcl | 254 | 241 |
| Tranexamic Acid | Tranexamic Acid | 241 | 229 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 132 | 113 |
| Baclofen | Baclofen | 117 | 93 |
| Meloxicam | Meloxicam | 77 | 66 |
| Clindamycin Hcl | Clindamycin Hcl | 74 | 40 |
| Ondansetron Odt | Ondansetron | 59 | 51 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 58 | 56 |
| Eliquis | Apixaban | 47 | 44 |
| Tramadol Hcl | Tramadol Hcl | 41 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 32 |
| Gabapentin | Gabapentin | 32 | 14 |
| Erythromycin | Erythromycin Base | 29 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | 11 |
| Zilretta | Triamcinolone Acetonide | 26 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206,576.34 · 198 records | Stryker Corporation | ACCOLADE, AEQUALIS, Avance, ETHICON, Exparel, GMRS, INSIGNIA, Iovera, JOURNAVX, MAKO, Mepilex Border Post-Op, Mepilex Border Post-Op Ag, PNB AND ACCESSORIES, Persona, Prospera Flex Negative Pressure Wound Therapy System, TMINI Miniature Robotic System, TRIATHLON, TRITANIUM, ZYNRELEF, Zilretta, mymobility Platform | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Zilretta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Pacira Pharmaceuticals Incorporated?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error